A Single Amino Acid Change Eliminated Cannabinoid Effects on Pain-Related Glycine Receptors
Mutating a single amino acid (serine to isoleucine at position 267) in the glycine receptor alpha1 subunit abolished the ability of CBD, ajulemic acid, and HU210 to modulate glycine receptor function.
Quick Facts
What This Study Found
Loss of inhibitory glycine signaling in the spinal cord plays a key role in chronic pain. Recent research suggested that cannabinoids might relieve pain partly by modulating glycine receptors, independent of cannabinoid receptors.
Researchers tested three non-psychotropic cannabinoids (ajulemic acid, CBD, and HU210) on glycine receptors with a specific mutation: serine to isoleucine at position 267 in the transmembrane domain.
This single amino acid change completely abolished the ability of all three cannabinoids to co-activate or directly activate glycine receptors.
This demonstrated that position 267 in the TM2 domain is crucial for cannabinoid-glycine receptor interactions, providing insight into the molecular basis of cannabinoid pain relief through non-CB1/CB2 mechanisms.
Key Numbers
One amino acid mutation (S267I) abolished all cannabinoid-glycine receptor interactions. Three cannabinoids tested: ajulemic acid, CBD, HU210. All effects eliminated by the mutation.
How They Did This
In vitro electrophysiology study. Mutated alpha1(S267I) glycine receptors were expressed in HEK293 cells and studied using whole-cell patch clamp technique. Three cannabinoids (ajulemic acid, cannabidiol, HU210) were tested for their ability to modulate glycine receptor currents.
Why This Research Matters
Understanding how cannabinoids relieve pain through non-cannabinoid receptor mechanisms (like glycine receptors) could lead to pain medications that work through the cannabinoid-glycine interaction without producing psychoactive effects.
The Bigger Picture
Pain relief through glycine receptor modulation represents a fundamentally different mechanism from traditional cannabinoid receptor activation. Drugs designed to exploit this specific interaction could potentially provide pain relief without the psychoactive effects or abuse potential of THC.
What This Study Doesn't Tell Us
In vitro study using recombinant receptors in cell lines, not native neurons. The mutation may affect receptor function in ways beyond cannabinoid interactions. Whether this mechanism contributes significantly to pain relief in living organisms was not tested.
Questions This Raises
- ?How important is glycine receptor modulation for the overall analgesic effect of cannabinoids?
- ?Could drugs be designed to specifically target the cannabinoid-glycine receptor interaction?
- ?Do natural variations in glycine receptor genes affect pain responses to cannabinoids?
Trust & Context
- Key Stat:
- One amino acid change abolished all cannabinoid-glycine receptor interactions
- Evidence Grade:
- In vitro electrophysiology study with recombinant receptors. Provides precise molecular data but limited translational relevance.
- Study Age:
- Published in 2010. The cannabinoid-glycine receptor interaction has continued to be studied as a potential target for non-psychoactive pain treatments.
- Original Title:
- Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids.
- Published In:
- Naunyn-Schmiedeberg's archives of pharmacology, 381(5), 477-82 (2010)
- Authors:
- Foadi, Nilufar(2), Leuwer, Martin(2), Demir, Reyhan(2), Dengler, Reinhard, Buchholz, Vanessa, de la Roche, Jeanne, Karst, Matthias, Haeseler, Gertrud, Ahrens, Jörg
- Database ID:
- RTHC-00412
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What are glycine receptors?
Glycine receptors are proteins in the spinal cord that normally inhibit pain signaling. When they are not working properly, chronic pain can develop. Some cannabinoids appear to enhance glycine receptor function, which may contribute to their pain-relieving effects.
Why does this matter for CBD pain relief?
CBD does not strongly bind to cannabinoid receptors (CB1/CB2), so its pain-relieving effects must involve other mechanisms. This study showed that CBD modulates glycine receptors, and identified the exact molecular site responsible, which could help develop targeted pain drugs.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00412APA
Foadi, Nilufar; Leuwer, Martin; Demir, Reyhan; Dengler, Reinhard; Buchholz, Vanessa; de la Roche, Jeanne; Karst, Matthias; Haeseler, Gertrud; Ahrens, Jörg. (2010). Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids.. Naunyn-Schmiedeberg's archives of pharmacology, 381(5), 477-82. https://doi.org/10.1007/s00210-010-0506-9
MLA
Foadi, Nilufar, et al. "Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids.." Naunyn-Schmiedeberg's archives of pharmacology, 2010. https://doi.org/10.1007/s00210-010-0506-9
RethinkTHC
RethinkTHC Research Database. "Lack of positive allosteric modulation of mutated alpha(1)S2..." RTHC-00412. Retrieved from https://rethinkthc.com/research/foadi-2010-lack-of-positive-allosteric
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.